Welcome to our dedicated page for TFA Therapeutics SEC filings (Ticker: RAJAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TFA Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TFA Therapeutics's regulatory disclosures and financial reporting.
TFA Therapeutics, Inc., formerly Cordyceps Sunshine Biotech Holdings Co., Ltd., reports that shareholders passed a special resolution on July 12, 2026 to change the company’s name to TFA Therapeutics, Inc. The certificate of incorporation on change of name was filed with the Cayman Islands Registry of Companies on July 20, 2026 and the completed certificate was received on July 22, 2026. The company’s ticker symbol remains unchanged.
Cordyceps Sunshine Biotech Holdings Co., Ltd. has entered a strategic Cooperation and Development Agreement with Pet Sunshine Biological Research Co., Ltd. covering the Antcin A (TFA-01) platform. Antcin A is positioned as a “Next-Generation Non-Steroidal Anti-Inflammatory Drug Platform” for both human and animal drug applications.
Pet Sunshine retains legal ownership of the Antcin A platform assets but grants Cordyceps Sunshine an exclusive, worldwide, royalty-free license to manage, develop, commercialize, license and pursue capital markets initiatives. Commercial revenues from Antcin A activities are, in principle, shared 50%/50% between the two parties.
The exclusive rights are intended to be irrevocable unless both parties agree in writing, and Pet Sunshine cannot enter conflicting deals without Cordyceps Sunshine’s consent. The agreement also grants Cordyceps Sunshine preemptive rights, rights of first refusal and a call option in certain change-of-control or breach scenarios, and is governed by Taiwan law with disputes resolved via arbitration in Taipei.
Cordyceps Sunshine Biotech Holdings reports 2025 revenue of $1,245,348, entirely from Cattle camphor mushroom (Taiwanofungus) products, and a net loss from continuing operations of $154,822. Gross margin was 61.09%, but the company highlights substantial doubt about its ability to continue as a going concern.
Working capital was deeply negative, with current assets of $997,742 and current liabilities of $5,192,062, leading to a shareholders’ deficit of $534,551. One third-party customer contributed 43.81% of 2025 revenue and a related-party customer 14.08%, while a single supplier provided 100% of raw materials.
The business depends on patented cultivation technology licensed from a founder, has no product liability or business interruption insurance, and operates mainly through a Taiwan branch. Two insiders indirectly control about 59.3% of ordinary shares, limiting minority shareholder influence.
Cordyceps Sunshine Biotech Holdings Co., Ltd. reported a change in its independent auditor. On November 15, 2025, the Board of Directors approved and ratified the appointment of YCM CPA INC. as the company’s new independent registered public accounting firm to audit its financial statements, effective the same day.
The report notes that during the two most recent fiscal years ended December 31, 2024 and 2023, and any subsequent interim periods before this engagement, neither the company nor anyone on its behalf consulted YCM CPA INC. on accounting matters. The filing also includes as an exhibit a letter from the previous auditor, KCCW Accountancy Corp., addressed to the U.S. Securities and Exchange Commission.
Cordyceps Sunshine Biotech Holdings Co., Ltd. amended its Form 20-F to provide updated annual disclosures about operations focused on Cordyceps and Antrodia products, manufacturing processes and cultivation techniques. The company reported training revenue of $154,107 for the period shown and a net income of $751,609 for the year ended December 31, 2023, reversing losses of $720,093 in 2022 and $491,006 in 2021. Management disclosed an accumulated deficit of $472,966 and negative working capital of $2,638,968 as of December 31, 2023, and stated substantial doubt about the company’s ability to continue as a going concern. The company recognized a $582,324 net gain from the reclassification and disposal of its Hong Kong subsidiary and recorded discontinued operations. Share ownership is highly concentrated with a controlling group holding approximately 59.3% of ordinary shares. Significant risks disclosed include customer and supplier concentration, regulatory and geopolitical risks related to PRC/Taiwan operations, and dependence on a limited product set.